All In Biotech

Drug Trial Radar · NCT07740512

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)

An Open-Label, Multicenter, Phase 2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients With Lysosomal Storage Disorders (SOTERIA)

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 31, 2028

Study completion Feb 1, 2029

Sponsor

Lead sponsor
Polaryx Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and clinical activity of PLX-200 in pediatric patients with lysosomal storage disorders.

Conditions

  • Lysosomal Storage Disorders
  • Sandhoff Disease
  • Krabbe Disease
  • CLN2
  • CLN3

Interventions

  • PLX-200Drug

    PLX-200 will be BID, with equal doses given approximately 12 hours apart, 30 minutes before the morning and evening meals, for 101 weeks (5-week Titration Period and 96-week Maintenance Period) based on each participant's weight. Dosing will begin with a 5-week TP based on the participant's weight group to achieve a target maintenance dose (TMD).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of PLX-200 in study participants 2 to 15 years old1 with LSDs2 during the treatment period.Time frame: Until 30 days after the last administration of the study drug.
  2. To evaluate the safety and tolerability of PLX-200 in study participants 2 to 15 years old1 with LSDs2 during the treatment period.Time frame: 30 days after the last administration of the study drug
  3. To evaluate the change from baseline in clinical laboratory parameters in study participants 2 to 15 years old with LSDs during the treatment period.Time frame: Week 102
  4. To evaluate the change from baseline in physical examination results in study participants 2 to 15 years old with LSDs during the treatment period.Time frame: Week 102
  5. To evaluate the change from baseline vital signs in study participants 2 to 15 years old with LSDs during the treatment period.Time frame: Week 102
  6. To evaluate the change from baseline in 12-lead electrocardiogram in study participants 2 to 15 years old with LSDs during the treatment period.Time frame: Week 102

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.